Rahul Aggarwal, Christina Bursill, Gemma A Figtree, Samantha L Hocking, R Preston Mason, Erin D Michos, Michael Miller, Adam J Nelson, Stephen J Nicholls, Kerry-Anne Rye, Ph Gabriel Steg, Gerald F Watts, Sophia Zoungas, Peter Libby
{"title":"Cardiovascular risk, evaluation and management in patients with hypertriglyceridaemia: a Consensus Statement from the International Atherosclerosis Society.","authors":"Rahul Aggarwal, Christina Bursill, Gemma A Figtree, Samantha L Hocking, R Preston Mason, Erin D Michos, Michael Miller, Adam J Nelson, Stephen J Nicholls, Kerry-Anne Rye, Ph Gabriel Steg, Gerald F Watts, Sophia Zoungas, Peter Libby","doi":"10.1038/s41569-026-01358-9","DOIUrl":"https://doi.org/10.1038/s41569-026-01358-9","url":null,"abstract":"<p><p>The prevalence of hypertriglyceridaemia is increasing globally owing to high rates of obesity and diabetes mellitus. Hypertriglyceridaemia is associated with an increased risk of cardiovascular disease, mediated through the cholesterol content of triglyceride-rich lipoprotein remnant particles rather than through triglycerides per se. Although plasma levels of triglycerides can be measured with a simple blood test, hypertriglyceridaemia remains underdiagnosed and undertreated. Hypertriglyceridaemia can result from various primary or secondary aetiologies, the identification and management of which is an important first step. Hypertriglyceridaemia can be managed with lifestyle measures, lipid-lowering therapy with statins in indicated patients to reduce cholesterol levels and, in refractory situations, with the addition of triglyceride-specific pharmacological therapies. Emerging therapies with considerable promise for the management of hypertriglyceridaemia include those targeting apolipoprotein C-III, angiopoietin-related protein 3 or fibroblast growth factor 21. However, so far, there is no evidence from randomized clinical trials that pharmacotherapies targeting triglycerides can reduce the occurrence of cardiovascular events, suggesting that elevated levels of triglycerides serve as a marker of atherosclerotic risk that should prompt optimization of modifiable cardiovascular risk factors. In this Consensus Statement, we provide clinical context and evidence for the evaluation, diagnosis and management of hypertriglyceridaemia.</p>","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149408495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kimon Stamatelopoulos, Georgios Georgiopoulos, Alberto Aimo, Evmorfia Aivalioti, Karen Carolyn Bauer, Simon Tual-Chalot, Simon Kraler, Dimitrios Bampatsias, Mario Nuvolone, Mahmoud Abdellatif, Dimitrios Delialis, Christoph Laske, Alexandros Briasoulis, Charalambos Vlachopoulos, Nektarios Tavernarakis, Michele Vendruscolo, Michele Emdin, Thorsten Hoppe, Ioannis Trougakos, Giovanni Palladini, Efstathios Kastritis, Mathew S Maurer, Marianna Fontana, Konstantinos Stellos
{"title":"Cardiac and vascular involvement in protein misfolding diseases.","authors":"Kimon Stamatelopoulos, Georgios Georgiopoulos, Alberto Aimo, Evmorfia Aivalioti, Karen Carolyn Bauer, Simon Tual-Chalot, Simon Kraler, Dimitrios Bampatsias, Mario Nuvolone, Mahmoud Abdellatif, Dimitrios Delialis, Christoph Laske, Alexandros Briasoulis, Charalambos Vlachopoulos, Nektarios Tavernarakis, Michele Vendruscolo, Michele Emdin, Thorsten Hoppe, Ioannis Trougakos, Giovanni Palladini, Efstathios Kastritis, Mathew S Maurer, Marianna Fontana, Konstantinos Stellos","doi":"10.1038/s41569-026-01359-8","DOIUrl":"https://doi.org/10.1038/s41569-026-01359-8","url":null,"abstract":"<p><p>Protein misfolding diseases impose a substantial and often under-recognized burden on both the heart and vasculature. In this Review, we outline how the failure of proteostasis drives oligomer toxicity, amyloid deposition and inflammation in cardiovascular tissues as well as microvascular injury and thrombosis, which culminate in cardiovascular dysfunction. We define the cardiovascular hallmarks of protein misfolding diseases, focusing on transthyretin amyloidosis and immunoglobulin light chain amyloidosis, and the disease-specific organ tropisms. We examine neurodegenerative proteinopathies affecting the heart-vascular-brain axis, highlighting how amyloid-β and α-synuclein accumulation contribute to dysautonomia, vascular dysfunction and adverse outcomes. We summarize diagnostic pathways and clinical indicators for early diagnosis of cardiovascular involvement in protein misfolding diseases and review established and emerging biomarkers of vascular stress and proteotoxic load. We also map the current therapeutic landscape for protein misfolding diseases, including strategies to reduce the synthesis of precursor proteins or promote the stabilization of mature proteins as well as fibril-directed therapies, and discuss remaining challenges, such as residual cardiovascular risk, that support the development of mechanism-informed therapeutic approaches. Finally, we propose a research roadmap that prioritizes systematic cardiovascular screening in at-risk populations, harmonized methods for vascular phenotyping, biomarker-anchored mechanistic clinical trials across protein misfolding diseases, and artificial intelligence-based approaches and precision medicine frameworks that integrate genotype or distinct protein conformational strain patterns, organ tropism and dynamic proteostasis measures.</p>","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pedro Carrera-Bastos, Abel Plaza-Florido, Inmaculada Pérez-Prieto, Shlomit Radom-Aizik, Claudio Franceschi, Carlos Rodríguez-López, José Antonio Serra-Rexach, Enzo Emanuele, Alejandro Lucia
{"title":"Cardiovascular resilience in centenarians.","authors":"Pedro Carrera-Bastos, Abel Plaza-Florido, Inmaculada Pérez-Prieto, Shlomit Radom-Aizik, Claudio Franceschi, Carlos Rodríguez-López, José Antonio Serra-Rexach, Enzo Emanuele, Alejandro Lucia","doi":"10.1038/s41569-026-01348-x","DOIUrl":"https://doi.org/10.1038/s41569-026-01348-x","url":null,"abstract":"<p><p>Centenarians - individuals aged ≥100 years - provide a unique human model for understanding resilience to cardiovascular ageing. Although cardiovascular and metabolic diseases, including hypertension, heart failure, atrial fibrillation and chronic kidney disease, are common in centenarians, their onset is typically delayed relative to that in individuals aged 80-100 years. Centenarians characteristically have structural changes in the heart and vessels, including concentric left ventricular remodelling, increased myocardial stiffness and vascular ageing, but often without the expected burden of myocardial infarction or overt heart failure. Their cardiometabolic profile is generally favourable, marked by preserved insulin sensitivity in cohorts with a low prevalence of diabetes mellitus, mid-range lipid levels and a low prevalence of obesity. Centenarians also have a distinctive inflammatory and gastrointestinal phenotype, characterized by chronic low-grade inflammation with elevated anti-inflammatory signalling, a gut microbiome that more closely resembles that of younger adults, and preserved intestinal barrier integrity. Genetically and epigenetically, exceptional longevity reflects highly polygenic contributions, selective maintenance of genomic stability and markedly younger epigenetic age compared with chronological age. In this Review, we summarize data on the cardiovascular system among centenarians by framing observations of longevity as a composite of delayed pathology, adaptive compensation and survivorship selection. Understanding the biological, behavioural and environmental mechanisms underlying cardiovascular resilience in extreme longevity might inform strategies to extend cardiovascular healthspan across all ages.</p>","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149270769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The evolution and future of conduction system pacing.","authors":"So-Ryoung Lee, Pugazhendhi Vijayaraman, Weijian Huang, Marek Jastrzębski, Jacqueline Joza, Haran Burri, Shunmuga Sundaram Ponnusamy, Roderick Tung, Daniel Lustgarten, Eue-Keun Choi","doi":"10.1038/s41569-026-01354-z","DOIUrl":"https://doi.org/10.1038/s41569-026-01354-z","url":null,"abstract":"<p><p>Cardiac pacing has undergone a fundamental paradigm shift from conventional right ventricular apical pacing towards physiological activation of the native conduction system of the heart. Decades of evidence have established that chronic right ventricular pacing induces ventricular dyssynchrony, contributing to pacing-induced cardiomyopathy and adverse clinical outcomes. Conduction system pacing, which engages the intrinsic His-Purkinje network of the heart, has emerged as a transformative approach that preserves or restores the natural ventricular activation sequence. His bundle pacing, the earliest form of conduction system pacing, provided proof of concept but is limited by technical challenges and high capture thresholds. Left bundle branch area pacing has since become the dominant modality, offering greater procedural success, lead stability and broader applicability: from management of bradycardia and prevention of pacing-induced cardiomyopathy to cardiac resynchronization therapy in heart failure. Bachmann bundle area pacing is an emerging atrial counterpart: by capturing a preferential interatrial conduction pathway, this approach reduces interatrial conduction delay and produces a more physiological atrial activation sequence than conventional right atrial appendage pacing. Bachmann bundle area pacing might, therefore, help to prevent atrial fibrillation. In this Review, we bring these ventricular and atrial strategies together under the unifying principle of physiological pacing, describe their mechanistic basis and technical evolution, appraise the latest evidence from randomized trials and address the practical questions that arise in clinical application, indicating where more evidence is required.</p>","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Münzel, Marin Kuntic, John F Keaney, Julia Lurz, Filippo Crea, Thomas F Lüscher, Sanjay Rajagopalan, Andreas Daiber
{"title":"Reply to 'Distinguishing between nicotine replacement therapies and nicotine-containing consumer products'.","authors":"Thomas Münzel, Marin Kuntic, John F Keaney, Julia Lurz, Filippo Crea, Thomas F Lüscher, Sanjay Rajagopalan, Andreas Daiber","doi":"10.1038/s41569-026-01361-0","DOIUrl":"https://doi.org/10.1038/s41569-026-01361-0","url":null,"abstract":"","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Duration of antibiotic treatment for infective endocarditis: should we move towards tailored therapy?","authors":"Mary Philip, Gilbert Habib","doi":"10.1038/s41569-026-01360-1","DOIUrl":"https://doi.org/10.1038/s41569-026-01360-1","url":null,"abstract":"","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Heart-specific T cell responses: from antigens to disease mechanisms.","authors":"Gustavo Campos Ramos","doi":"10.1038/s41569-026-01356-x","DOIUrl":"https://doi.org/10.1038/s41569-026-01356-x","url":null,"abstract":"<p><p>The field of immunology has transformed our understanding of myocardial cell biology and paved the way for new pathophysiological concepts in cardiology. Researchers have sought to elucidate the contributions of nonspecific inflammatory mechanisms to cardiac diseases, and an increasing number of clinical trials have explored anti-inflammatory approaches in cardiovascular disease. Moreover, adaptive immune mechanisms directed to cardiac proteins released by dying cardiomyocytes have been reported across a broad spectrum of conditions, including acute myocarditis, myocardial infarction and heart failure, and have gained increasing attention. This concept of antigen-specific cardio-immune crosstalk could pave the way for a deeper understanding of tissue-specific disease mechanisms and facilitate the development of targeted interventions. However, only a small number of cardiac antigens have been identified so far, and an immunological definition of heart specificity remains elusive. This Review revisits the molecular composition of the heart from the perspective of T cells to describe the most relevant cardiac antigens identified to date, thus defining a framework for identifying novel T cell reactivities in the injured heart. Going forward, these insights might pave the way for the development of new tools to track specific T cells across various cardiac diseases, in contexts ranging from model organisms to patients.</p>","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}